About: Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children
Creator	Fukaya, Takashi Matsubara, Kousaku Nigami, Hiroyuki Tamura, Akihiro Tanaka, Takayuki Yura, Kazuo
Source	Elsevier; Medline; PMC
abstract	Summary Objectives To determine the efficacy of methylprednisolone pulse therapy for children with Mycoplasma pneumoniae pneumonia (MP) that is refractory to antibiotic treatment. Methods Refractory patients were defined as cases showing clinical and radiological deterioration despite appropriate antibiotic therapy for 7 days or more. We identified 6 such children (male/female: 3/3) aged 3–9 years who were treated between 1998 and 2006. During the same period, 190 children with MP were admitted to our institution. Results Common laboratory findings of the patients included cytopenia, elevated serum lactate dehydrogenase and ferritin levels, and elevated urine β2-microglobulin levels, suggesting complication of hypercytokinemic condition. We initiated intravenous methylprednisolone at a dose of 30mg/kg on 10.2±2.8 clinical days and administered it once daily for 3 consecutive days. Fever subsided 4–14h after initiation of steroid pulse therapy in all patients. This dramatic effect was accompanied by rapid improvement of radiological abnormalities including infiltrates and pleural effusion, followed by improvement of laboratory abnormalities. There were no adverse events of steroid therapy. Conclusions This is the first case-series study showing an effect of 3-day methylprednisolone pulse therapy on refractory MP in children. This therapy is apparently an efficacious and well-tolerated treatment for refractory MP.
has issue date	2008-09-30(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2008.06.012
bibo:pmid	18656264
has license	els-covid
sha1sum (hex)	11573d3bd32381c341555e51b00b7d39c5104439
schema:url	https://doi.org/10.1016/j.jinf.2008.06.012
resource representing a document's title	Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children
has PubMed Central identifier	PMC7112643
has PubMed identifier	18656264
schema:publication	Journal of Infection
resource representing a document's body	covid:11573d3bd32381c341555e51b00b7d39c5104439#body_text
is schema:about of	named entity 'This' named entity 'improvement' named entity 'cytopenia' named entity 'urine' named entity 'intravenous' named entity 'pulse' named entity 'therapy' named entity 'REFRACTORY' named entity 'TREATED' named entity 'METHYLPREDNISOLONE PULSE THERAPY' named entity 'DEFINED' named entity 'ADMITTED TO' named entity 'OUR' named entity 'COMPLICATION' named entity 'LEVELS' named entity 'INCLUDING' covid:arg/11573d3bd32381c341555e51b00b7d39c5104439 named entity 'DETERMINE' named entity 'STEROID THERAPY' named entity 'IDENTIFIED' named entity 'SERUM LACTATE DEHYDROGENASE' named entity 'FERRITIN LEVELS' named entity 'MG%' named entity 'OBJECTIVES' named entity 'YEARS' named entity '1998' named entity 'TREATMENT' named entity 'AE 2' named entity 'CYTOPENIA' named entity 'URINE' named entity 'RESULTS' named entity 'LABORATORY ABNORMALITIES' named entity 'INITIATION' named entity 'LABORATORY' named entity 'PLEURAL EFFUSION' named entity 'FOR CHILDREN' named entity 'MICROGLOBULIN' named entity 'DETERIORATION' named entity 'CHILDREN' named entity 'DOSE' named entity 'MYCOPLASMA PNEUMONIAE PNEUMONIA' named entity 'CHILDREN' named entity 'METHYLPREDNISOLONE PULSE THERAPY' named entity 'ELEVATED' named entity 'CONCLUSIONS' named entity 'INTRAVENOUS' named entity 'FOLLOWED BY' named entity 'APPARENTLY' named entity '190' named entity 'THERAPY' named entity 'RAPID' named entity 'FEVER' named entity 'DAYS' named entity 'CASES' named entity 'ELEVATED SERUM LACTATE' named entity 'APPROPRIATE' named entity 'PERIOD' named entity 'CLINICAL' named entity 'MYCOPLASMA PNEUMONIAE PNEUMONIA' named entity 'FINDINGS' named entity 'CONSECUTIVE DAYS' named entity 'STUDY' named entity 'ABNORMALITIES' named entity 'CASE' named entity 'COMMON' named entity 'INFILTRATES' named entity 'ANTIBIOTIC TREATMENT' named entity 'ANTIBIOTIC THERAPY' named entity 'IMPROVEMENT' named entity 'ONCE DAILY' named entity 'CONDITION' named entity 'AGED' named entity 'METHODS' named entity 'SERIES' named entity 'DAY' named entity 'PATIENTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software